Phaseline

Targets › SLC6A6

SLC6A6 (Sodium- and chloride-dependent taurine transporter): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Mediates sodium- and chloride-dependent transport of taurine, a key amino acid. Taurine acts as an anti-aging agent by reducing cellular senescence and combating oxidative stress: levels decline with age and supplementation has been shown to extend lifespan (By similarity). (UniProt, P31641)

Open in Phaseline: the race on SLC6A6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shandong Cancer Hospital and InstituteTaurine
Amino acid with antioxidant and cytoprotective properties; taurine transporter substrate
SLC6A6Phase 1To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer PatientsSep 2027

Conditions

To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients (1)

Modalities

–

Companies

Shandong Cancer Hospital and Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.